Global Smart Insulin Pens s valued approximately USD 89.53 million in 2020and is anticipated to grow with a healthy growth rate of more than 10.77% over the forecast period 2021-2027.Diabetes is a major health problem that is rapidly increasing in the global population; therefore, the use of good internal secretion pens is significantfor the safe and effective administration of internal secretion to individuals suffering from polygenic disorder. Internal secretion pens are used to deliver internal secretion outwardly, provides higher polygenic diabetes management system. The increase in polygenic disorder cases boost the market growth. One of the key factors working in favour of the global market is the growing number of diabetics as a result of obesity, inactive lifestyles, and ageing. Fatness has emerged as one of the leading causes of polygenic disorder in people. Undernutrition are the first links to polygenic disorder cases, which are increasing at epidemic proportions. As a result of the large number of people affected by polygenic disorder, the market for sensible internal secretion pens is expanding globally.Smart insulin pens support in calculating personalized doses, continuously tracking glucose, and connecting with smartphone apps to visualize data. Moreover, Novo Nordisk and Abbott collaborated in 2019 to integrate insulin dose data into digital health tools, with the goal of connecting key technologies such as continuous glucose monitoring and insulin pen market size worldwide.Strict government regulations and high cost are the restraining factors of the market. North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa make up the global smart insulin pens industry. North America is the industry leader for smart insulin pens, accounting for more than half of overall sales in 2017. Furthermore, North America generates the most sales due to the involvement of major players and a high rate of adoption of technologically advanced products. Furthermore, Asia Pacific is expected to expand rapidly over the forecast period. This is due to a rise in the number of geriatrics with diabetes, which is fueling the growth of the smart insulin pens market in this area.
Major market player included in this report are:
Companion Medical Inc.
Digital Medics Ptd Ltd.
Eli Lilly and Company
Novo Nordisk A/S
Diamesco Co., Ltd.
F. Hoffmann-La Roche AG
Insulet Corporation
Emperra GmbH E-Health Technologies
Jiangsu Delfu medical device Co. Ltd.
Bigfoot biomedica.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product
Second Generation Pens
USB Connected Smart Insulin Pen
Bluetooth-Enabled Smart Insulin Pen
First Generation Pens
By Usability
Prefilled
Reusable
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
Home care settings
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year 2018, 2019
Base year 2020
Forecast period 2021 to 2027
Target Audience of the Smart Insulin Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors